The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.

The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce- cultured mammalian cells for therapeutic of diagnostic purposes.

The present disclosure provides engineered gram-positive microbes that are able to fix atmospheric nitrogen and deliver such to plants in a targeted, efficient, and environmentally sustainable manner. The utilization of the taught microbial products will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived nitrogen fertilizer.

Provided herein are compositions and methods to make and use engineered cells, for the purpose of increasing the cell density of a culture comprising metazoan cells and for the production of a cultured edible product.

The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia. In particular the invention relates to the systemic administration of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods, and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.

The present invention relates to the treatment of fatty liver disease, by administration of glutamine synthetase.

This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.

Glutamine synthetase mutant having glufosinate ammonium resistance, application thereof and a cultivation method therefor. Comparing with the reference sequence, the amino acid sequence of the glutamine synthetase mutant has one or a combination of the following mutations: (1) the amino acid of the glutamine synthetase mutant corresponding to amino acid site 59 of the reference sequence is mutated to X.sub.1, wherein X.sub.1=A, C, D, E, F, G, H, I, K, P, T, V or Y; (2) the amino acid of the glutamine synthetase mutant corresponding to amino acid site 296 of the reference sequence is mutated to X.sub.2, wherein X.sub.2=A, D, E, G, I, K, M, P, Q, R, S, T, or V.

Inventions disclosed herein relates to vectors and expression systems for producing heteromeric recombinant proteins such as monoclonal antibodies. Vectors and expression systems disclosed herein are based on the finding that the selectable marker glutamine synthetase can be divided into two fragments at selected amino acid positions of the glutamine synthetase polypeptide, and the two fragments can internet and/or associate to form a monomer and then a functional multimeric glutamine synthetase protein. Z

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.